MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
BPC-157 + TB-500 Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
The BPC-157 and TB-500 stack pairs Sikiric's pentadecapeptide Body Protection Compound with the N-terminal actin-binding fragment of thymosin beta-4 on the rationale that the two peptides act on largely non-overlapping repair pathways: BPC-157 primarily upregulates VEGFR2-driven angiogenesis, modulates nitric oxide synthesis, and influences dopaminergic and serotonergic tone in injured tissue, while TB-500 sequesters monomeric G-actin to promote cytoskeletal remodeling, cell migration, VEGF expression, and bone marrow-derived endothelial progenitor recruitment to wound sites. Researchers and unsupervised users combine them for tendon, ligament, and muscle injury recovery, post-surgical wound healing, and inflammatory bowel disease models, with the hypothesis that simultaneous angiogenic stimulation and cytoskeletal mobilization compound the single-agent effects. Mechanistic context is provided in PMID 30915550 (Sikiric BPC-157 review) and PMID 17204577 (Goldstein thymosin beta-4 review). No randomized human trial has formally evaluated the combination, so additive benefit is inferred from single-agent animal data only.
Reconstitute: Add 3 mL bacteriostatic water → 3.33 mg/mL concentration.
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL = 0.0333 mg (33 mcg) on a U-100 insulin syringe.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Half-life profile: BPC-157 is short in plasma but stable in gastric juice; TB-500 has a much longer 2 to 3 day plasma half-life, so combined protocols often pair daily BPC-157 with twice-weekly TB-500.
Onset: Soft-tissue symptom changes are reported in anecdotal human reports over 2 to 4 weeks; controlled animal models show histologic and functional healing in 7 to 21 days with single-agent dosing.
Regulatory status: Neither component is approved by FDA, EMA, or other major regulators. Both are WADA-prohibited (BPC-157 added under S0; TB-500 under S2). FDA 503A category 2 listing restricts US compounding access for BPC-157.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming or vigorous shaking.
Gently swirl/roll until fully dissolved (do not shake).
Inject slowly; wait a few seconds before withdrawing the needle.
Do not aspirate for subcutaneous injections; inject slowly and steadily[13].
Interactive BPC-157 + TB-500 Syringe Calculator
Currently visualizing the 10 mg vial reconstituted with 3 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 10mg dry powder in 3mL water yields 3.33 mg/mL. To evaluate a 250mcg dose, pull to 7.5 units (8 syringe ticks).
U-100 Syringe Representation
7.5 Units (8 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase / Week | Daily Dose (Total Blend) | Each Peptide (mcg) | Units (mL) |
|---|---|---|---|
| Weeks 1–2 (Initial) | 600 mcg | 300 mcg BPC + 300 mcg TB-500 | 18 units (0.18 mL) |
| Weeks 3–4 (Loading) | 800 mcg | 400 mcg BPC + 400 mcg TB-500 | 24 units (0.24 mL) |
| Weeks 5–8 (Maintenance) | 600 mcg | 300 mcg BPC + 300 mcg TB-500 | 18 units (0.18 mL) |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
| Phase / Week | Daily Dose (Total Blend) | Each Peptide (mcg) | Units (mL) |
|---|---|---|---|
| Weeks 1–2 (Aggressive Load) | 1000 mcg | 500 mcg BPC + 500 mcg TB-500 | 30 units (0.30 mL) |
| Weeks 3–4 (High Load) | 800 mcg | 400 mcg BPC + 400 mcg TB-500 | 24 units (0.24 mL) |
| Weeks 5–8 (Maintenance) | 600 mcg | 300 mcg BPC + 300 mcg TB-500 | 18 units (0.18 mL) |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 10 mg vial.
Peptide Vials (BPC-157 + TB-500, 10 mg blend each):
- check8 weeks ≈ 4 vials
- check12 weeks ≈ 6 vials
- check16 weeks ≈ 8 vials
Insulin Syringes (U-100):
- checkPer week: 7 syringes (1/day)
- check8 weeks: 56 syringes
- check12 weeks: 84 syringes
- check16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- check8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- check12 weeks (6 vials): 18 mL → 2 × 10 mL bottles
- check16 weeks (8 vials): 24 mL → 3 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- checkPer week: 14 swabs (2/day)
- check8 weeks: 112 swabs → recommend 2 × 100-count boxes
- check12 weeks: 168 swabs → recommend 2 × 100-count boxes
- check16 weeks: 224 swabs → recommend 3 × 100-count boxes
Mechanism of Action (MOA)
The mechanistic rationale for stacking BPC-157 with TB-500 is complementary pharmacology that addresses different phases and tissue compartments of the wound healing cascade. BPC-157 is a 15-amino-acid peptide (GEPPPGKPADDAGLV) derived from a partial sequence of Body Protection Compound originally isolated from human gastric juice by Sikiric and colleagues; its principal mechanisms include upregulation of VEGFR2 on endothelial cells with downstream activation of the Akt-eNOS axis to drive angiogenesis, ERK1/2 activation in fibroblasts and muscle satellite cells, and upregulation of growth hormone receptor expression in tendon fibroblasts to sensitize them to anabolic signaling [1][2][7]. TB-500 corresponds to the actin-binding region of thymosin beta-4 (Tbeta4); the full-length 43-amino-acid Tbeta4 is the most abundant intracellular G-actin-sequestering protein, with downstream effects on cell migration through regulated actin polymerization, endothelial cell motility, anti-inflammatory cytokine modulation, and recruitment of progenitor cells to sites of injury [3][4][6]. The two peptides therefore converge on the regenerative cascade from different directions: BPC-157 builds the vascular infrastructure required for sustained tissue regeneration, while TB-500 mobilizes the cellular machinery (fibroblasts, keratinocytes, endothelial cells, progenitor cells) that must migrate to and operate within that vascular framework. Pharmacokinetically the two peptides are quite different. BPC-157 is unusually stable in gastric juice and serum, allowing oral, subcutaneous, and intramuscular administration with comparable downstream effects; precise plasma half-life data are sparse but tissue retention is substantial. TB-500 has a plasma half-life of approximately 2 hours after subcutaneous injection but its biological effects are largely tissue-incorporated and persist for days. The combination is typically administered by separate subcutaneous injections rather than a mixed-vial single injection to permit independent dosing schedules. The most commonly cited protocol pairs BPC-157 at 250 to 500 mcg/day given by subcutaneous injection near the site of injury or in the abdomen, with TB-500 at 2 to 5 mg twice weekly given subcutaneously in the abdomen or thigh during a 4 to 6 week loading phase. After loading, the maintenance phase typically reduces TB-500 to 2 mg once weekly for an additional 4 to 8 weeks while continuing BPC-157 at the same daily dose. Cycle length varies by indication: acute soft tissue injury cohorts often run 4 to 6 week cycles; chronic tendinopathy and post-surgical recovery research may extend to 8 to 12 weeks; gastrointestinal applications may use shorter BPC-157-dominant protocols without TB-500. Common research applications include Achilles tendinopathy and rupture, rotator cuff and biceps tendon injury, ACL reconstruction recovery, hamstring and quadriceps strain, chronic plantar fasciitis, and post-surgical orthopedic recovery. The combination is on the WADA Prohibited List under category S2 and is banned in competitive sport.
Clinical Trial Efficacy Highlights
- starSikiric and colleagues have published over 200 preclinical papers demonstrating that BPC-157 accelerates tendon, ligament, muscle, bone, and gastrointestinal healing through VEGFR2-mediated angiogenesis and growth-factor signaling pathways, providing the foundational preclinical evidence for the BPC-157 component of the stack [1][5].
- starChang and colleagues demonstrated in the Journal of Applied Physiology that BPC-157 significantly accelerated tendon outgrowth, fibroblast survival under oxidative stress, and cell migration in scratch assays, providing the mechanism of tendon healing relevant to the stack's orthopedic applications [2].
- starGoldstein, Hannappel, and Kleinman summarized in Trends in Molecular Medicine the wound healing, angiogenic, and anti-inflammatory mechanisms of thymosin beta-4 and TB-500, providing the foundational evidence base for the TB-500 component of the combination [3].
- starCrockford, Turjman, Allan, and Angel reviewed in Annals of the New York Academy of Sciences the structure, function, and biological properties of TB-500 supporting clinical applications across wound, cardiac, and corneal repair, providing the translational framework for TB-500 use in healing protocols [4].
- starA phase 2 study of topical thymosin beta-4 (the parent molecule of TB-500) in venous stasis ulcers showed complete healing in approximately 25 percent of treated patients within 3 months, supporting the biological activity of the TB-500 region in human wound healing [6].
- starBock-Marquette and colleagues demonstrated in mouse models of myocardial infarction that thymosin beta-4 administration reduced infarct size and preserved cardiac function through integrin-linked kinase activation, providing evidence of multi-tissue regenerative activity that complements BPC-157's angiogenic mechanism [8].
- starMechanistic studies in tendon fibroblasts have shown that BPC-157 upregulates growth hormone receptor expression by approximately 3-fold at mRNA and protein levels, providing a novel mechanism of amplifying anabolic signaling at injury sites that complements the actin-mediated cell migration effects of TB-500 [7].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningEach component peptide is broadly described as well tolerated in preclinical studies and the limited human pilot literature, with no serious adverse events attributable to the combination specifically; however no controlled trial of the stack itself has been published.
- warningInjection site reactions including mild erythema, transient pain, and pruritus are common with both peptides; using separate injection sites or alternating thigh and abdomen reduces local discomfort.
- warningTheoretical concerns about angiogenesis-related effects on occult malignancy exist with both peptides because VEGFR2-driven angiogenesis (BPC-157) and progenitor mobilization (TB-500) could theoretically support tumor growth; the combination doubles the theoretical concern, although no direct clinical evidence of tumor promotion has been demonstrated.
- warningBoth peptides are on the WADA Prohibited List; the combination is banned in competitive sport at all times, in and out of competition.
- warningLong-term safety data are essentially absent; published human exposure to either component is limited to short-term courses, and combined chronic dosing safety has not been characterized.
- warningUse in pregnancy, lactation, and pediatric populations is not recommended for either component or the combination; teratogenicity studies meeting modern regulatory standards have not been published.
- warningDrug-drug interactions are theoretically minimal because neither peptide engages cytochrome P450 metabolism, but pharmacodynamic interactions with anticoagulants and growth factors are theoretically possible.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical BPC-157 and TB-500 dosage?expand_more
The most commonly cited protocol pairs BPC-157 at 250 to 500 mcg/day subcutaneously with TB-500 at 2 to 5 mg twice weekly during a 4 to 6 week loading phase, followed by maintenance of TB-500 at 2 mg once weekly for an additional 4 to 8 weeks while continuing BPC-157 daily.
How is BPC-157 and TB-500 used in research protocols?expand_more
Common research applications include Achilles tendinopathy and rupture, rotator cuff injury, ACL reconstruction recovery, muscle strain, and post-surgical orthopedic recovery. Outcome measures include return-to-activity timelines, ultrasound and MRI imaging, biomechanical testing, and validated functional scores.
Can BPC-157 and TB-500 be combined with other peptides?expand_more
The BPC-157 plus TB-500 stack is itself the core of broader healing protocols that may add KPV (anti-inflammatory) and GHK-Cu (tissue remodeling, copper-mediated antioxidant effects). Growth hormone secretagogues such as ipamorelin and CJC-1295 are also sometimes added for systemic anabolic support.
What are the side effects of BPC-157 and TB-500?expand_more
Most users report mild injection site reactions, occasional transient fatigue during loading, and rare mild gastrointestinal effects. Theoretical concerns about angiogenesis effects on occult malignancy exist with both peptides. The combination is banned in competitive sport by WADA.
Is BPC-157 and TB-500 FDA approved?expand_more
No. Neither BPC-157 nor TB-500 is FDA approved, and the combination has no regulatory status. In late 2023 the FDA placed BPC-157 in Category 2 of its 503A compounding list, effectively restricting compounded pharmacy access in the United States.
Academic References & Study Citations
Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol. 2021;12:627533. View Scientific Paper →
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. View Scientific Paper →
Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. View Scientific Paper →
Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179-189. View Scientific Paper →
Sikiric P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993;87(5):313-327. View Scientific Paper →
Guarnera G, DeRosa A, Camerini R. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010;1194:207-212. View Scientific Paper →
Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. View Scientific Paper →
Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. View Scientific Paper →
Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. Curr Sports Med Rep. 2025;24(8):278-289. View Scientific Paper →
Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. View Scientific Paper →